The Drug That Nobody Talks About Enough: Regeneron's Hidden Compounding Machine

Analysis done February 26, 2026 | Quality Compounder | Part 3 of 3

Part 1: Gilead Sciences (GILD): The Fortress Nobody's Paying Attention To | GNG Research

Part 2: Part 2 of 3: The Night the Organ Monopoly Proved It Was Real | GNG Research

Rating: BUY (Staged, Pullback Discipline) | 12-Month Target: $900 | Close: $789.54

Wall Street has spent 18 months arguing about what Regeneron is losing. The EYLEA cliff. Biosimilar creep. The eye franchise that built the company slowly giving ground to cheaper competitors. It's a legitimate worry, and it has kept the stock range-bound while the S&P rallied around it.

But here's the thing about tunnel vision: when everyone's watching the same exit, they miss what's walking in the front door.

This week, Regeneron's (REGN) "other" business, the one the market has largely treated as a footnote, just quietly got more valuable. On February 24, the FDA expanded Dupixent's label again, this time for allergic fungal rhinosinusitis (AFRS), adding yet another addressable patient population to a drug that already treats eczema, asthma, nasal polyps, eosinophilic esophagitis, and COPD. Four days earlier, the FDA accepted the company's BLA for garetosmab with Priority Review status, validating a rare disease program that most models assign zero credit for.

The question for investors isn't whether Regeneron is a good company. It obviously is: 98th percentile quality score, 120x interest coverage, Altman Z-Score of 7.8, and a debt-to-equity ratio so low (0.1) it barely registers. The question is whether it's a good buy at these prices. The honest answer: not quite yet. But get the entry right, and you're holding one of the most durable franchises in biopharma at a price that doesn't require perfection.

The Business They Built and the Transition They're Managing